In 2016 the FDA relaxed botanical drug approval guidelines to catch up with global standards, creating a huge opportunity for the worldwide expansion of botanical medicine. The global botanical medicine industry is an open and untapped $300 billion market. PhytaZenica ("fi-duh-zeh-ni-kuh") is a healthcare tech company that provides digital products and services to accelerate the development and approval of botanical medicine.